GSK and Pfizer Stipulate to Dismissal of RSV Vaccines Lawsuit

On April 3, 2025, GlaxoSmithKline (GSK) and Pfizer filed a stipulation to dismiss with prejudice GSK’s litigation in the United States District Court for the District of Delaware.  GSK filed suit in August 2023, alleging that Pfizer’s respiratory syncytial …

Pfizer agrees to pay GSK royalties as part of global RSV patent settlement

MargJohnsonVA/Shutterstock Innovator-versus-innovator disputes and licensing increasingly common in life sciences Register for limited access Register to receive our newsletter and gain limited access to subscriber content. Register now Subscribe to …

RSV poses greater risk than flu for older adults, expert warns

An expert recently recommended vaccination against respiratory syncytial virus (RSV) for people aged 60 and older, as well as for those with certain underlying medical conditions. RSV is an acute respiratory infection classified as a legal Category 4 …

Older Adults Have Low Knowledge of RSV Disease and Vaccine Eligibility

RSV may elevate risk for stroke, heart failure hospitalization

April 07, 2025 4 min read Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Respiratory …

GSK and Pfizer resolve RSV vaccine patent fight

GSK and Pfiz­er have set­tled a law­suit al­leg­ing Pfiz­er’s RSV shot Abrys­vo in­fringed GSK’s patents. A Pfiz­er spokesper­son told End­points News that as part of … Sign up to read this article for free. Get free access to a limited number of articles, …

Study Reveals Low RSV Knowledge and Vaccine Uptake Among Hospitalized Older Adults

Knowledge about respiratory syncytial virus (RSV) and vaccine eligibility was limited among hospitalized adults, according to findings published by investigators in JAMA Network Open. Despite this, a significant portion of unvaccinated patients expressed …

GSK, Pfizer resolve RSV patent feud amid vaccine market uncertainty

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory uncertainties, GSK and Pfizer have decided to lay to rest their patent feud. GSK and Pfizer have moved to scrap a patent lawsuit …

GSK resolves patent lawsuit against Pfizer over RSV vaccines

By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent rights in its competing RSV shot …

VDH: COVID-19 continues to wane

Report Timeframe: March 23 to March 29, 2025. Current Vermont Department of Health recommendations on preventing COVID-19. by Timothy McQuiston, Vermont Business Magazine The Vermont Department of Health reported last week that the number of COVID-19 …